国产精品视频一区二区三区四,亚洲av美洲av综合av,99国内精品久久久久久久,欧美电影一区二区三区电影

產品推薦:氣相|液相|光譜|質譜|電化學|元素分析|水分測定儀|樣品前處理|試驗機|培養(yǎng)箱


化工儀器網>技術中心>儀器文獻>正文

歡迎聯系我

有什么可以幫您? 在線咨詢

Nanobrook Omni測量應用案例-32

來源:美國布魯克海文儀器公司   2018年08月13日 14:19  
 文獻名:Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer 

 

作者:Tanaya Vaidya1, Robert M. Straubinger2, Sihem Ait-Oudhia1 

    1.Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy University of Florida, Orlando, USA

    2.Department of Pharmaceutical Sciences University at Buffalo, State University of New York, Buffalo, USA

 

摘要:

Purpose

Trastuzumab combined with Doxorubicin (DOX) demonstrates significant clinical activity in human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC). However, emergence of treatment resistance and trastuzumab associated cardiotoxicity remain clinical challenges. In an effort to improve patient outcome, we have developed and evaluated novel tri-functional immunoliposomes (TFIL) that target HER2-receptors on BC cells and CD3-receptors on T-lymphocytes, and deliver DOX.

 

Methods

Trastuzumab (anti-HER2) and OKT-3 (anti-CD3) antibodies were conjugated to liposomes using a micelle-transfer method. Cytotoxicity of targeted immunoliposomes loaded with DOX was examined in vitro on HER2-positive BC cells (BT474), with peripheral blood monocytic cells (PBMC) as immune effector cells.

 

Results

TFIL demonstrated high antibody-liposome conjugation ratios (100130 μg protein/μmol phospholipid) and cargo capacity (0.21 mol:mol drug:lipid), highly efficient DOX loading (>90%), a particle size favorable for extended circulation (~150 nm), and good stability (up to 3 months at 4°C). In the presence of PBMCs, TFIL showed complete killing of BT474 cells, and were superior to mono-targeted trastuzumab-bearing liposomes, non-targeted liposomes, and free Trastuzumab and DOX.

 

Conclusions

Novel anti-HER2xCD3+DOX TFIL show promise as a means to both engage immune cells against HER2 positive breast cancer cells and deliver chemotherapy, and have the potential to improve clinical outcomes.

免責聲明

  • 凡本網注明“來源:化工儀器網”的所有作品,均為浙江興旺寶明通網絡有限公司-化工儀器網合法擁有版權或有權使用的作品,未經本網授權不得轉載、摘編或利用其它方式使用上述作品。已經本網授權使用作品的,應在授權范圍內使用,并注明“來源:化工儀器網”。違反上述聲明者,本網將追究其相關法律責任。
  • 本網轉載并注明自其他來源(非化工儀器網)的作品,目的在于傳遞更多信息,并不代表本網贊同其觀點和對其真實性負責,不承擔此類作品侵權行為的直接責任及連帶責任。其他媒體、網站或個人從本網轉載時,必須保留本網注明的作品第一來源,并自負版權等法律責任。
  • 如涉及作品內容、版權等問題,請在作品發(fā)表之日起一周內與本網聯系,否則視為放棄相關權利。
企業(yè)未開通此功能
詳詢客服 : 0571-87858618
府谷县| 比如县| 鹿邑县| 富裕县| 石城县| 肥城市| 靖安县| 任丘市| 年辖:市辖区| 井冈山市| 大同县| 洪江市| 科技| 衡南县| 凌海市| 咸丰县| 宽城| 宽甸| 桃园市| 涟源市| 新津县| 井陉县| 阿图什市| 杭锦旗| 孟连| 阿克苏市| 博乐市| 甘孜| 盐池县| 尼勒克县| 新化县| 宁远县| 丹阳市| 石家庄市| 木里| 渑池县| 龙胜| 清流县| 垫江县| 徐水县| 邵东县|